CTLA4 and melanoma: For example, therapeutic regimens targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed death 1 (PD-1) increase tumor regression rates from less than 10% to nearly 50% in patients with advanced melanoma [2].